Supports· moderateORCH-E009
β-tubulin identified as a direct anesthetic target with functional consequences in vivo
- what the source states
- The abstract reports that the general anesthetic 1-aminoanthracene photolabeled β-tubulin, identified by mass spectrometry, with binding localized near the colchicine site; that the compound inhibited microtubule polymerization in vitro; and that pretreatment of tadpoles with the microtubule stabilizers epothilone D and discodermolide increased the concentration of anesthetic required to produce immobilization. The authors conclude that microtubules are "on-pathway targets" for this class of anesthetic.
- what we infer
- The best causal molecular evidence in the case that tubulin can lie on an anesthetic pathway, and it is strengthened rather than weakened by its provenance: this comes from an established anesthesia-mechanisms laboratory with no Orch OR commitment, which found the result while asking a different question. Two limits on its reach. The anesthetic is a research compound rather than a clinical volatile, so generalization is not established. And the epothilone-D direction here — stabilization producing anesthetic *resistance* — is opposite to the chronic epothilone-D result in mice (ORCH-E013), which is one more reason the stabilizer literature does not cohere into a rule.
- limitations
- 1-aminoanthracene is a research anesthetic; results may not generalize to clinical volatile or intravenous agents.
- Tadpole immobilization endpoint, which is an immobility rather than hypnosis measure.
- Binding near the colchicine site implies ordinary pharmacological interaction; nothing quantum is measured or implied.
- The authors' own conclusion is the modest 'on-pathway targets', not a mechanism claim.